Education
About Us
Working with TipRanks
Follow Us
Theratechnologies Inc (THTX)
NASDAQ:THTX
THTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $3.20
Previous CloseN/A
Volume43.44K
Average Volume (3M)631.87K
Market Cap
$145.60M
Enterprise Value$962.44M
Total Cash (Recent Filing)$4.34M
Total Debt (Recent Filing)$50.35M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Oct 09, 2025EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding45,980,020
10 Day Avg. Volume1,632,185
30 Day Avg. Volume631,874
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)-36.84
Price to Sales (P/S)0.00
P/FCF Ratio-53.04
Enterprise Value/Market Cap6.61
Enterprise Value/Revenue2.82
Enterprise Value/Gross Profit13.75
Enterprise Value/Ebitda28.90
Forecast
1Y Price Target
$2.56Price Target Upside-18.47% Downside
Rating ConsensusHold
Number of Analyst Covering2
Theratechnologies News
PremiumCompany Announcements
Theratechnologies Reports Q2 2025 Earnings and Acquisition
PremiumCompany Announcements
Theratechnologies Reports Q2 2025 Financial Results and Acquisition Agreement
Bulls Say, Bears Say
Bulls Say
Acquisition PremiumThe combined cash and CVR price for Theratechnologies represents a 216% premium to shareholders.
Patent ProtectionPatent protection for EGRIFTA WR extends into 2033, providing long-term security for the product.
Product InnovationEGRIFTA WR offers improved convenience to HIV patients with lipodystrophy, requiring weekly reconstitution versus daily and less total volume.
Bears Say
Acquisition UncertaintyThere is skepticism about the success of Future Pak's acquisition offer, and it is likely to fall through despite recognizing the value of the EGRIFTA franchise.
Supply DisruptionAn expected one-time reduction in revenue due to a supply disruption resulted in a $10M — $12M decrease for FY25.
Transparency ConcernsTheratechnologies confirmed it does not intend to provide updates or comments on the ongoing negotiations unless required by law, creating a lack of transparency for investors.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
21.43% Other Institutional Investors
78.46% Public Companies and Individual Investors
THTX FAQ
What was Theratechnologies Inc’s price range in the past 12 months?
Theratechnologies Inc lowest stock price was $1.12 and its highest was $3.20 in the past 12 months.
What is Theratechnologies Inc’s market cap?
Theratechnologies Inc’s market cap is $145.60M.
When is Theratechnologies Inc’s upcoming earnings report date?
Theratechnologies Inc’s upcoming earnings report date is Oct 09, 2025 which is in 91 days.
How were Theratechnologies Inc’s earnings last quarter?
Theratechnologies Inc released its earnings results on Jul 09, 2025. The company reported -$0.015 earnings per share for the quarter, the consensus estimate of -$0.015 by $0.
Is Theratechnologies Inc overvalued?
According to Wall Street analysts Theratechnologies Inc’s price is currently Overvalued.
Does Theratechnologies Inc pay dividends?
Theratechnologies Inc does not currently pay dividends.
What is Theratechnologies Inc’s EPS estimate?
Theratechnologies Inc’s EPS estimate is 0.04.
How many shares outstanding does Theratechnologies Inc have?
Theratechnologies Inc has 45,980,020 shares outstanding.
What happened to Theratechnologies Inc’s price movement after its last earnings report?
Theratechnologies Inc reported an EPS of -$0.015 in its last earnings report, expectations of -$0.015. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Theratechnologies Inc?
Currently, no hedge funds are holding shares in THTX
Theratechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.56 (-18.47% Downside)
$2.56 (-18.47% Downside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 12.9%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.69%
Trailing 12-Months
Company Description
Theratechnologies Inc
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
THTX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and new product approval, indicating positive market momentum. However, challenges such as the drug shortage and declining Trogarzo sales were significant concerns. The company's strategic focus on transitioning to the new product formulation and managing operational efficiencies shows resilience.Read More>THTX Stock 12 Month Forecast
Average Price Target
$2.56
▼(-18.47%Downside)
Technical Analysis
Cipher Pharmaceuticals
―
Crescita Therpeutc
―
Medicure
―
Biosyent
―
HLS Therapeutics Inc
―